Rezolute Inc.

08/05/2024 | Press release | Distributed by Public on 08/05/2024 05:33

Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.